managed to get out above 50 cents. Good luck all. Capex of nearly $400m and lack of re-rating means a good chance TMT will never develop this Hope it finishes at 60 cents for ya all
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%